摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-[4-(3-methoxyphenyl)butyl]-4-phenylpiperazine | 1610999-41-1

中文名称
——
中文别名
——
英文名称
1-[4-(3-methoxyphenyl)butyl]-4-phenylpiperazine
英文别名
——
1-[4-(3-methoxyphenyl)butyl]-4-phenylpiperazine化学式
CAS
1610999-41-1
化学式
C21H28N2O
mdl
——
分子量
324.466
InChiKey
RIESGYNOLFLRSK-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.84
  • 重原子数:
    24.0
  • 可旋转键数:
    7.0
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.43
  • 拓扑面积:
    15.71
  • 氢给体数:
    0.0
  • 氢受体数:
    3.0

反应信息

  • 作为反应物:
    描述:
    1-[4-(3-methoxyphenyl)butyl]-4-phenylpiperazine三溴化硼 作用下, 以 二氯甲烷 为溶剂, 反应 2.0h, 以73%的产率得到3-[4-(4-phenylpiperazin-1-yl)butyl]phenol
    参考文献:
    名称:
    Towards the development of 5-HT7 ligands combining serotonin-like and arylpiperazine moieties
    摘要:
    Many known 5-HT7 ligands contain either a serotonin-like or an arylpiperazine structure that, in published SAR studies, are generally supposed to bind the same receptor pocket. Conversely, we explored the hypothesis that two such moieties can co-exist in the same ligand, binding to different pockets. We thus designed and synthesized a set of compounds including both a 5-hydroxyindol-3-ylethyl and a 1-arylpiperazine moieties connected by a short linker. The compounds were tested for their affinity for human 5-HT7 serotonin receptor. We further prepared a novel series of 5-HT7 ligands, where the 5-hydroxyindol-3-ylethyl moiety was bioisosterically replaced by a 3-hydroxyanilinoalkyl one. Among the newly synthesized compounds, potent ligands at the 5-HT7 receptor, behaving as antagonists in functional tests, were identified, even if they showed limited subtype selectivity. Docking studies within a model of the 5-HT7 receptor showed that the binding site can actually accommodate both moieties, with the serotonin-like one in the putative orthosteric site and the arylpiperazine one occupying an accessory pocket. The present results demonstrate that it is possible to devise and develop new 5-HT7 ligands merging two privileged structures in the same molecule.
    DOI:
    10.1016/j.ejmech.2014.04.034
  • 作为产物:
    描述:
    4-(3-methoxyphenyl)-1-(4-phenylpiperazin-1-yl)butan-1-onediborane(6) 作用下, 以 四氢呋喃 为溶剂, 反应 4.0h, 以67%的产率得到1-[4-(3-methoxyphenyl)butyl]-4-phenylpiperazine
    参考文献:
    名称:
    Towards the development of 5-HT7 ligands combining serotonin-like and arylpiperazine moieties
    摘要:
    Many known 5-HT7 ligands contain either a serotonin-like or an arylpiperazine structure that, in published SAR studies, are generally supposed to bind the same receptor pocket. Conversely, we explored the hypothesis that two such moieties can co-exist in the same ligand, binding to different pockets. We thus designed and synthesized a set of compounds including both a 5-hydroxyindol-3-ylethyl and a 1-arylpiperazine moieties connected by a short linker. The compounds were tested for their affinity for human 5-HT7 serotonin receptor. We further prepared a novel series of 5-HT7 ligands, where the 5-hydroxyindol-3-ylethyl moiety was bioisosterically replaced by a 3-hydroxyanilinoalkyl one. Among the newly synthesized compounds, potent ligands at the 5-HT7 receptor, behaving as antagonists in functional tests, were identified, even if they showed limited subtype selectivity. Docking studies within a model of the 5-HT7 receptor showed that the binding site can actually accommodate both moieties, with the serotonin-like one in the putative orthosteric site and the arylpiperazine one occupying an accessory pocket. The present results demonstrate that it is possible to devise and develop new 5-HT7 ligands merging two privileged structures in the same molecule.
    DOI:
    10.1016/j.ejmech.2014.04.034
点击查看最新优质反应信息